Suppr超能文献

在表达人载脂蛋白E3、E2(精氨酸158→半胱氨酸)和E3-莱顿的小鼠肝脏中乳糜微粒残粒的摄取

Chylomicron remnant uptake in the livers of mice expressing human apolipoproteins E3, E2 (Arg158-->Cys), and E3-Leiden.

作者信息

Lee Sung-Joon, Grosskopf Itamar, Choi Sungshin Y, Cooper Allen D

机构信息

Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.

出版信息

J Lipid Res. 2004 Dec;45(12):2199-210. doi: 10.1194/jlr.M400284-JLR200. Epub 2004 Oct 1.

Abstract

Apolipoprotein E2 (apoE2) and apoE3-Leiden cause chylomicron remnant accumulation (type III hyperlipidemia). However, the degree of dyslipidemia and its penetrance are different in humans and mice. Remnant uptake by isolated liver from apoE-/- mice transgenic for human apoE2, apoE3-Leiden, or apoE3 was measured. In the presence of both LDL receptor (LDLR) and LDL receptor-related protein (LRP), remnant uptake was apoE3>E3-Leiden>E2 mice. Absence of LDLR reduced uptake in apoE3 and apoE3-Leiden-secreting livers but not in apoE2-secreting livers. LRP inhibition with receptor-associated protein reduced uptake in apoE3- and apoE2-secreting livers, but not in apoE3-Leiden-secreting livers, regardless of the presence of LDLR. Fluorescently labeled remnants clustered with LRP in apoE3-secreting livers only in the absence of LDLR, but clustered in livers that expressed apoE2 even in the presence of LDLR, and did not cluster with LRP in livers of apoE3-Leiden even in the absence of LDLR. Remnants were reconstituted with the three human apoE isoforms. Removal by liver of mApoe-/-/mldlr-/- mice expressing the human LDLR was slightly greater than removal in the previous experiments with apoE3>E2> E3-Leiden. Thus, in vivo, human apoE2 is cleared primarily by LRP, apoE3-Leiden is cleared only by the LDLR, and apoE3 is cleared by both.

摘要

载脂蛋白E2(apoE2)和apoE3-莱顿突变体可导致乳糜微粒残粒蓄积(III型高脂血症)。然而,人类和小鼠的血脂异常程度及其外显率有所不同。我们检测了转人类apoE2、apoE3-莱顿突变体或apoE3基因的apoE-/-小鼠的离体肝脏对残粒的摄取情况。在同时存在低密度脂蛋白受体(LDLR)和低密度脂蛋白受体相关蛋白(LRP)的情况下,残粒摄取量为apoE3>E3-莱顿突变体>E2小鼠。缺乏LDLR会降低apoE3和分泌apoE3-莱顿突变体的肝脏对残粒的摄取,但不会降低分泌apoE2的肝脏对残粒的摄取。用受体相关蛋白抑制LRP会降低分泌apoE3和apoE2的肝脏对残粒的摄取,但不会降低分泌apoE3-莱顿突变体的肝脏对残粒的摄取,无论是否存在LDLR。仅在不存在LDLR时,荧光标记的残粒才会在分泌apoE3的肝脏中与LRP聚集,但在存在LDLR时,即使在表达apoE2的肝脏中残粒也会聚集,而在apoE3-莱顿突变体的肝脏中,即使不存在LDLR,残粒也不会与LRP聚集。残粒用三种人类载脂蛋白E异构体进行了重组。表达人类LDLR的mApoe-/-/mldlr-/-小鼠肝脏对残粒的清除率略高于之前用apoE3>E2>E3-莱顿突变体进行的实验中的清除率。因此,在体内,人类apoE2主要通过LRP清除,apoE3-莱顿突变体仅通过LDLR清除,而apoE3则通过两者清除。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验